Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations

Shoji Ichikawa, Geneviève Baujat, Aksel Seyahi, Anastasia G. Garoufali, Erik Imel, Leah R. Padgett, Anthony M. Austin, Andrea H. Sorenson, Zagorka Pejin, Vicken Topouchian, Pierre Quartier, Valerie Cormier-Daire, Michele Dechaux, Fotini Ch Malandrinou, Panagiotis N. Singhellakis, Martine Le Merrer, Michael Econs

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

The GALNT3 gene encodes GalNAc-T3, which prevents degradation of the phosphaturic hormone, fibroblast growth factor 23 (FGF23). Biallelic mutations in either GALNT3 or FGF23 result in hyperphosphatemic familial tumoral calcinosis or its variant, hyperostosis-hyperphosphatemia syndrome. Tumoral calcinosis is characterized by the presence of ectopic calcifications around major joints, whereas hyperostosis - hyperphosphatemia syndrome is characterized by recurrent long bone lesions with hyperostosis. Here we investigated four patients with hyperphosphatemia and clinical manifestations including tumoral calcinosis and/or hyperostosis - hyperphosphatemia syndrome to determine underlying genetic cause and delineate phenotypic heterogeneity of these disorders. Mutational analysis of FGF23 and GALNT3 in these patients revealed novel homozygous mutations in GALNT3. Although the presence of massive calcifications, cortical hyperostosis, or dental anomalies was not shared by all patients, all had persistent hyperphosphatemia. Three of the patients also had inappropriately normal 1,25-dihyroxyvitamin D [1,25(OH)2D] and confirmed low circulating intact FGF23 concentrations. The four novel GALNT3 mutations invariably resulted in hyperphosphatemia as a result of low intact FGF23, but other clinical manifestations were variable. Therefore, tumoral calcinosis and hyperostosis - hyperphosphatemia syndrome represent a continuous spectrum of the same disease caused by increased phosphate levels, rather than two distinct disorders.

Original languageEnglish
Pages (from-to)896-903
Number of pages8
JournalAmerican Journal of Medical Genetics, Part A
Volume152
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Calcinosis
Hyperphosphatemia
Mutation
Hyperostosis
Tooth
Joints
Phosphates
fibroblast growth factor 23
Hormones
Bone and Bones
Hyperostosis-hyperphosphatemia syndrome
Genes

Keywords

  • FGF23
  • GALNT3
  • Hyperostosis - Hyperphosphatemia syndrome
  • Phosphate
  • Tumoral calcinosis

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. / Ichikawa, Shoji; Baujat, Geneviève; Seyahi, Aksel; Garoufali, Anastasia G.; Imel, Erik; Padgett, Leah R.; Austin, Anthony M.; Sorenson, Andrea H.; Pejin, Zagorka; Topouchian, Vicken; Quartier, Pierre; Cormier-Daire, Valerie; Dechaux, Michele; Malandrinou, Fotini Ch; Singhellakis, Panagiotis N.; Le Merrer, Martine; Econs, Michael.

In: American Journal of Medical Genetics, Part A, Vol. 152, No. 4, 04.2010, p. 896-903.

Research output: Contribution to journalArticle

Ichikawa, S, Baujat, G, Seyahi, A, Garoufali, AG, Imel, E, Padgett, LR, Austin, AM, Sorenson, AH, Pejin, Z, Topouchian, V, Quartier, P, Cormier-Daire, V, Dechaux, M, Malandrinou, FC, Singhellakis, PN, Le Merrer, M & Econs, M 2010, 'Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations', American Journal of Medical Genetics, Part A, vol. 152, no. 4, pp. 896-903. https://doi.org/10.1002/ajmg.a.33337
Ichikawa, Shoji ; Baujat, Geneviève ; Seyahi, Aksel ; Garoufali, Anastasia G. ; Imel, Erik ; Padgett, Leah R. ; Austin, Anthony M. ; Sorenson, Andrea H. ; Pejin, Zagorka ; Topouchian, Vicken ; Quartier, Pierre ; Cormier-Daire, Valerie ; Dechaux, Michele ; Malandrinou, Fotini Ch ; Singhellakis, Panagiotis N. ; Le Merrer, Martine ; Econs, Michael. / Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. In: American Journal of Medical Genetics, Part A. 2010 ; Vol. 152, No. 4. pp. 896-903.
@article{c840455e9f8c474993900b857438b8c1,
title = "Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations",
abstract = "The GALNT3 gene encodes GalNAc-T3, which prevents degradation of the phosphaturic hormone, fibroblast growth factor 23 (FGF23). Biallelic mutations in either GALNT3 or FGF23 result in hyperphosphatemic familial tumoral calcinosis or its variant, hyperostosis-hyperphosphatemia syndrome. Tumoral calcinosis is characterized by the presence of ectopic calcifications around major joints, whereas hyperostosis - hyperphosphatemia syndrome is characterized by recurrent long bone lesions with hyperostosis. Here we investigated four patients with hyperphosphatemia and clinical manifestations including tumoral calcinosis and/or hyperostosis - hyperphosphatemia syndrome to determine underlying genetic cause and delineate phenotypic heterogeneity of these disorders. Mutational analysis of FGF23 and GALNT3 in these patients revealed novel homozygous mutations in GALNT3. Although the presence of massive calcifications, cortical hyperostosis, or dental anomalies was not shared by all patients, all had persistent hyperphosphatemia. Three of the patients also had inappropriately normal 1,25-dihyroxyvitamin D [1,25(OH)2D] and confirmed low circulating intact FGF23 concentrations. The four novel GALNT3 mutations invariably resulted in hyperphosphatemia as a result of low intact FGF23, but other clinical manifestations were variable. Therefore, tumoral calcinosis and hyperostosis - hyperphosphatemia syndrome represent a continuous spectrum of the same disease caused by increased phosphate levels, rather than two distinct disorders.",
keywords = "FGF23, GALNT3, Hyperostosis - Hyperphosphatemia syndrome, Phosphate, Tumoral calcinosis",
author = "Shoji Ichikawa and Genevi{\`e}ve Baujat and Aksel Seyahi and Garoufali, {Anastasia G.} and Erik Imel and Padgett, {Leah R.} and Austin, {Anthony M.} and Sorenson, {Andrea H.} and Zagorka Pejin and Vicken Topouchian and Pierre Quartier and Valerie Cormier-Daire and Michele Dechaux and Malandrinou, {Fotini Ch} and Singhellakis, {Panagiotis N.} and {Le Merrer}, Martine and Michael Econs",
year = "2010",
month = "4",
doi = "10.1002/ajmg.a.33337",
language = "English",
volume = "152",
pages = "896--903",
journal = "American Journal of Medical Genetics, Part C: Seminars in Medical Genetics",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations

AU - Ichikawa, Shoji

AU - Baujat, Geneviève

AU - Seyahi, Aksel

AU - Garoufali, Anastasia G.

AU - Imel, Erik

AU - Padgett, Leah R.

AU - Austin, Anthony M.

AU - Sorenson, Andrea H.

AU - Pejin, Zagorka

AU - Topouchian, Vicken

AU - Quartier, Pierre

AU - Cormier-Daire, Valerie

AU - Dechaux, Michele

AU - Malandrinou, Fotini Ch

AU - Singhellakis, Panagiotis N.

AU - Le Merrer, Martine

AU - Econs, Michael

PY - 2010/4

Y1 - 2010/4

N2 - The GALNT3 gene encodes GalNAc-T3, which prevents degradation of the phosphaturic hormone, fibroblast growth factor 23 (FGF23). Biallelic mutations in either GALNT3 or FGF23 result in hyperphosphatemic familial tumoral calcinosis or its variant, hyperostosis-hyperphosphatemia syndrome. Tumoral calcinosis is characterized by the presence of ectopic calcifications around major joints, whereas hyperostosis - hyperphosphatemia syndrome is characterized by recurrent long bone lesions with hyperostosis. Here we investigated four patients with hyperphosphatemia and clinical manifestations including tumoral calcinosis and/or hyperostosis - hyperphosphatemia syndrome to determine underlying genetic cause and delineate phenotypic heterogeneity of these disorders. Mutational analysis of FGF23 and GALNT3 in these patients revealed novel homozygous mutations in GALNT3. Although the presence of massive calcifications, cortical hyperostosis, or dental anomalies was not shared by all patients, all had persistent hyperphosphatemia. Three of the patients also had inappropriately normal 1,25-dihyroxyvitamin D [1,25(OH)2D] and confirmed low circulating intact FGF23 concentrations. The four novel GALNT3 mutations invariably resulted in hyperphosphatemia as a result of low intact FGF23, but other clinical manifestations were variable. Therefore, tumoral calcinosis and hyperostosis - hyperphosphatemia syndrome represent a continuous spectrum of the same disease caused by increased phosphate levels, rather than two distinct disorders.

AB - The GALNT3 gene encodes GalNAc-T3, which prevents degradation of the phosphaturic hormone, fibroblast growth factor 23 (FGF23). Biallelic mutations in either GALNT3 or FGF23 result in hyperphosphatemic familial tumoral calcinosis or its variant, hyperostosis-hyperphosphatemia syndrome. Tumoral calcinosis is characterized by the presence of ectopic calcifications around major joints, whereas hyperostosis - hyperphosphatemia syndrome is characterized by recurrent long bone lesions with hyperostosis. Here we investigated four patients with hyperphosphatemia and clinical manifestations including tumoral calcinosis and/or hyperostosis - hyperphosphatemia syndrome to determine underlying genetic cause and delineate phenotypic heterogeneity of these disorders. Mutational analysis of FGF23 and GALNT3 in these patients revealed novel homozygous mutations in GALNT3. Although the presence of massive calcifications, cortical hyperostosis, or dental anomalies was not shared by all patients, all had persistent hyperphosphatemia. Three of the patients also had inappropriately normal 1,25-dihyroxyvitamin D [1,25(OH)2D] and confirmed low circulating intact FGF23 concentrations. The four novel GALNT3 mutations invariably resulted in hyperphosphatemia as a result of low intact FGF23, but other clinical manifestations were variable. Therefore, tumoral calcinosis and hyperostosis - hyperphosphatemia syndrome represent a continuous spectrum of the same disease caused by increased phosphate levels, rather than two distinct disorders.

KW - FGF23

KW - GALNT3

KW - Hyperostosis - Hyperphosphatemia syndrome

KW - Phosphate

KW - Tumoral calcinosis

UR - http://www.scopus.com/inward/record.url?scp=77950395245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950395245&partnerID=8YFLogxK

U2 - 10.1002/ajmg.a.33337

DO - 10.1002/ajmg.a.33337

M3 - Article

C2 - 20358599

AN - SCOPUS:77950395245

VL - 152

SP - 896

EP - 903

JO - American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

JF - American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

SN - 1552-4825

IS - 4

ER -